FOLH1 and acute myeloid leukemia: The preclinical data demonstrated that the modular CAR system is tuneable, easy to control, and has good efficacy in vivo, which led to the initiation of two clinical trials: NCT04230265 targeting CD123 in AML patients and NCT04633148 using PSMA as a target for prostate cancer.